Compare Barclays PLC (BCS) vs Koninklijke Philips NV (PHG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Barclays PLC vs Koninklijke Philips NV — how do they compare? Barclays PLC trades at $27.86 (market cap $90.80B), while Koninklijke Philips NV trades at $26.45 (market cap $26.67B). The key difference: Barclays PLC is far larger — about 3.4× Koninklijke Philips NV's market cap, and Koninklijke Philips NV pays the higher dividend (3.71%). Which is the better fit depends on your goals.
| BCS | PHG | |
|---|---|---|
Market Cap | $90.80B | $26.67B |
Sector | Financials | Health |
52-Week High | $28.41 | $32.91 |
52-Week Low | $18.48 | $24.11 |
Dividend Yield | 1.68% | 3.71% |
Enterprise Value | — | $32.93B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Barclays PLC (BCS) trades at $27.29, down 0.69% on the day, near its 52-week high of $28.43. The stock shows strong fundamental momentum with revenue rising to $29.14B in 2025 and net income reaching $7.17B, supported by three consecutive quarterly EPS beats. Technical indicators signal a bullish trend, while analyst sentiment remains positive with 68% buy ratings. Recent news highlights ongoing legal investigations but also underscores the bank's role in market analysis and product innovation.
The outlook for BCS is cautiously optimistic, driven by solid earnings growth and attractive valuation metrics like a P/E of 11.91 and P/B of 0.91. Key risks include potential legal liabilities from securities investigations and macroeconomic sensitivity. Investors should weigh the strong analyst support against these headwinds for balanced decision-making.
PHG trades at $27.34, down 0.22% on the day, with a bearish technical signal despite recent earnings beats. The company shows improving fundamentals with net income turning positive to $895M in 2025 after previous losses, supported by strong operating cash flow of $1.17B. Recent FDA clearances for AI-powered medical devices and strategic healthcare partnerships demonstrate innovation momentum.
The stock presents a mixed outlook with 41% analyst buy ratings but bearish technical indicators. Key opportunities include AI healthcare adoption and margin expansion, while risks involve competitive pressures and debt levels. Valuation appears reasonable with P/E of 24.01 and P/S of 1.31, but requires monitoring of execution against growth expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Barclays PLC
Barclays is a universal bank headquartered in the United Kingdom. It operates via two principal segments
Read more on BCS →About Koninklijke Philips NV
Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →
